Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 2;11:21478. doi: 10.1038/s41598-021-00945-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Anti-angiogenic activity of Eupafolin. (A,B) Human umbilical vein endothelial cells (HUVECs) were treated with Eupafolin at concentrations of 0, 25, 50 and 100 μM for 24, 48, and 72 h, respectively. Cell viability was evaluated by the CCK-8 assay and cell colony formation assay. (C) HUVECs were treated with Eupafolin at concentrations of 0, 50, and 100 μM for 24 h, and then subjected to apoptotic analysis by flow cytometry (lower panel). (D) HUVECs treated with Eupafolin at concentrations of 0, 10, and 20 mg/ml were subjected to the migration and invasion assay and observed at 24 h, respectively. (E) HUVECs treated with Eupafolin at concentrations of 0, 50, and 100 μM for 6 h were subjected to the tube formation assay. Data is representative of three independent experiments and expressed as mean ± SD. P > 0.05 indicates non-significance; ***P < 0.001; **P < 0.01; *P < 0.05.